Evoq Remedies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:25 pm

Quick Insight

Evoq Remedies Ltd, operating in the pharmaceutical industry, currently trades at a price of 3.20 with a market cap of 7.97 Cr. The company's P/E ratio stands at 88.6, indicating a relatively high valuation compared to its earnings. Despite a low ROE of 0.26% and ROCE of 0.35%, Evoq Remedies faces challenges with a negative operating profit margin at -5.10%. The firm's net profit is at 0.09, while reserves total 19.64 Cr. With no borrowings and a low P/BV ratio of 0.14x, Evoq Remedies shows a weak ICR at 0.00x. The company's CCC of 231.85 days suggests a need for improved cash flow management. In conclusion, investors should approach Evoq Remedies with caution due to its poor financial performance metrics and operational challenges.

Competitors of Evoq Remedies Ltd

All Competitor Stocks of Evoq Remedies Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:06 am

Below is a detailed analysis of the quarterly data for Evoq Remedies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 11.76 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 11.76 Cr., marking an increase of 11.76 Cr..
• For Expenses, as of Mar 2025, the value is 12.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.63 Cr. (Sep 2024) to 12.36 Cr., marking an increase of 10.73 Cr..
• For Operating Profit, as of Mar 2025, the value is -0.60 Cr.. The value appears strong and on an upward trend. It has increased from -1.63 Cr. (Sep 2024) to -0.60 Cr., marking an increase of 1.03 Cr..
• For OPM %, as of Mar 2025, the value is -5.10%. The value appears to be declining and may need further review. It has decreased from 0.00% (Sep 2024) to -5.10%, marking a decrease of 5.10%.
• For Other Income, as of Mar 2025, the value is 2.40 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Sep 2024) to 2.40 Cr., marking an increase of 2.39 Cr..
• For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
• For Depreciation, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.04 Cr..
• For Profit before tax, as of Mar 2025, the value is 1.76 Cr.. The value appears strong and on an upward trend. It has increased from -1.62 Cr. (Sep 2024) to 1.76 Cr., marking an increase of 3.38 Cr..
• For Tax %, as of Mar 2025, the value is 2.27%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Sep 2024) to 2.27%, marking an increase of 2.27%.
• For Net Profit, as of Mar 2025, the value is 1.71 Cr.. The value appears strong and on an upward trend. It has increased from -1.62 Cr. (Sep 2024) to 1.71 Cr., marking an increase of 3.33 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.69. The value appears strong and on an upward trend. It has increased from -0.65 (Sep 2024) to 0.69, marking an increase of 1.34.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 3:35 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:19 pm

Below is a detailed analysis of the balance sheet data for Evoq Remedies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 24.90 Cr.. The value appears strong and on an upward trend. It has increased from 13.60 Cr. (Mar 2024) to 24.90 Cr., marking an increase of 11.30 Cr..
• For Reserves, as of Mar 2025, the value is 19.64 Cr.. The value appears strong and on an upward trend. It has increased from 11.64 Cr. (Mar 2024) to 19.64 Cr., marking an increase of 8.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.24 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 4.24 Cr..
• For Other Liabilities, as of Mar 2025, the value is 5.47 Cr.. The value appears to be improving (decreasing). It has decreased from 7.39 Cr. (Mar 2024) to 5.47 Cr., marking a decrease of 1.92 Cr..
• For Total Liabilities, as of Mar 2025, the value is 50.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36.87 Cr. (Mar 2024) to 50.01 Cr., marking an increase of 13.14 Cr..
• For Fixed Assets, as of Mar 2025, the value is 0.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Mar 2024) to 0.22 Cr., marking an increase of 0.21 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 49.79 Cr.. The value appears strong and on an upward trend. It has increased from 36.86 Cr. (Mar 2024) to 49.79 Cr., marking an increase of 12.93 Cr..
• For Total Assets, as of Mar 2025, the value is 50.01 Cr.. The value appears strong and on an upward trend. It has increased from 36.87 Cr. (Mar 2024) to 50.01 Cr., marking an increase of 13.14 Cr..

Notably, the Reserves (19.64 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Evoq Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 0.33 (Mar 24) to 0.05, marking a decrease of 0.28.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.72. It has increased from 2.98 (Mar 24) to 4.72, marking an increase of 1.74.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.07, marking a decrease of 0.38.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.33 (Mar 24) to 0.03, marking a decrease of 0.30.
• For PBDIT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has decreased from 15.26 (Mar 24) to 1.50, marking a decrease of 13.76.
• For PBIT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
• For PBT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
• For Net Profit Margin (%), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 5. It has decreased from 11.16 (Mar 24) to 0.75, marking a decrease of 10.41.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 15. It has decreased from 1.79 (Mar 24) to 0.19, marking a decrease of 1.60.
• For Return on Capital Employeed (%), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 10. It has decreased from 2.42 (Mar 24) to 0.28, marking a decrease of 2.14.
• For Return On Assets (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 1.22 (Mar 24) to 0.17, marking a decrease of 1.05.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. It has increased from 0.11 (Mar 24) to 0.27, marking an increase of 0.16.
• For Current Ratio (X), as of Mar 25, the value is 9.10. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 9.10, marking an increase of 5.93.
• For Quick Ratio (X), as of Mar 25, the value is 8.69. This value exceeds the healthy maximum of 2. It has increased from 2.90 (Mar 24) to 8.69, marking an increase of 5.79.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Enterprise Value (Cr.), as of Mar 25, the value is 6.16. It has decreased from 15.91 (Mar 24) to 6.16, marking a decrease of 9.75.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 3.92 (Mar 24) to 0.52, marking a decrease of 3.40.
• For EV / EBITDA (X), as of Mar 25, the value is 34.78. This value exceeds the healthy maximum of 15. It has increased from 25.71 (Mar 24) to 34.78, marking an increase of 9.07.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
• For Price / BV (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.14, marking a decrease of 0.32.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness